Decoding kinase-adverse event associations for small molecule kinase inhibitors

Autor: Xiajing Gong, Meng Hu, Jinzhong Liu, Geoffrey Kim, James Xu, Amy McKee, Todd Palmby, R. Angelo de Claro, Liang Zhao

Publikováno v: Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)

Small molecule kinase inhibitors (SMKIs) are being approved at a fast pace under expedited programs for anticancer treatment. Here, the authors employ a machine-learning model to examine the relationships between kinase targets and adverse events in

Externí odkaz: https://doaj.org/article/0acfd12fa2c4416da16ad933f8db2dd9

Considerations for Drug Development in Myelodysplastic Syndromes

Autor: Mikkael A. Sekeres, Nina Kim, Amy E. DeZern, Kelly J. Norsworthy, Jacqueline S. Garcia, R. Angelo de Claro, Marc R. Theoret, Emily Y. Jen, Lori A. Ehrlich, Amer M. Zeidan, Rami S. Komrokji

Publikováno v: Clinical Cancer Research. :OF1-OF7

Myelodysplastic syndromes (MDS) have historically been challenging diseases for drug development due to their biology, preclinical modeling, and the affected patient population. In April 2022, the FDA convened a panel of regulators and academic exper

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c352e0dbb06a72c48acb8bede57cf850
https://doi.org/10.1158/1078-0432.ccr-22-3348

Data from The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018

Autor: Kathleen A. Cronin, Angela B. Mariotto, Amy E. Wood, R. Angelo de Claro, Nicole J. Gormley, Nicholas C. Richardson, Lori A. Ehrlich, Manami Bhattacharya, Elad Sharon, Nadia Howlader

Introduction:Molecularly targeted therapies such as tyrosine kinase inhibitors (TKI) are effective treatments for B-cell receptor (BCR)-ABL–bearing leukemias. We evaluated the impact of TKIs on historical chronic myeloid leukemia (CML) mortality tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1608fc95c4bc943532fef93efcac9e5
https://doi.org/10.1158/1055-9965.c.6628385

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

Autor: Gita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, Nicole Gormley, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Yok Lam Kwong, Richard F Little, Matthew J Matasar, Maria-Victoria Mateos, Kristen McCullough, Robert S Miller, Mohamad Mohty, Philippe Moreau, Lindsay M Morton, Sumimasa Nagai, Abhilasha Nair, Loretta Nastoupil, Kaye Robertson, Surbhi Sidana, Karin E Smedby, Pieter Sonneveld, Kyriaki Tzogani, Flora E van Leeuwen, Galina Velikova, Diego Villa, John R Wingard, John F Seymour, Thomas M Habermann

Publikováno v: Thanarajasingam, G, Minasian, L M, Bhatnagar, V, Cavalli, F, De Claro, R A, Dueck, A C, El-Galaly, T C, Everest, N, Geissler, J, Gisselbrecht, C, Gormley, N, Gribben, J, Horowitz, M, Ivy, S P, Jacobson, C A, Keating, A, Kluetz, P G, Kwong, Y L, Little, R F, Matasar, M J, Mateos, M-V, McCullough, K, Miller, R S, Mohty, M, Moreau, P, Morton, L M, Nagai, S, Nair, A, Nastoupil, L, Robertson, K, Sidana, S, Smedby, K E, Sonneveld, P, Tzogani, K, van Leeuwen, F E, Velikova, G, Villa, D, Wingard, J R, Seymour, J F & Habermann, T M 2022, ' Reaching beyond maximum grade : progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies ', The Lancet. Haematology, vol. 9, no. 5, pp. e374-e384 . https://doi.org/10.1016/S2352-3026(22)00045-X
Lancet Haematol

Remarkable improvements in outcomes for many haematological malignancies have been driven primarily by a proliferation of novel therapeutics over the past two decades. Targeted agents, immune and cellular therapies, and combination regimens have adve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2405df3e3651e395b828efbe04d1d737
https://doi.org/10.1016/s2352-3026(22)00045-x

FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial

Autor: E Dianne, Pulte, Haiyan, Chen, Lauren S L, Price, Ramadevi, Gudi, Hongshan, Li, Olanrewaju O, Okusanya, Lian, Ma, Lisa, Rodriguez, Jonathon, Vallejo, Kelly J, Norsworthy, R Angelo, de Claro, Marc R, Theoret, Richard, Pazdur

Publikováno v: Oncologist

On December 18, 2020, US Food and Drug Administration (FDA) approved a supplemental application for ponatinib extending the indication in patients with chronic-phase chronic myeloid leukemia (CP-CML) to patients with resistance or intolerance of at l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51adba305e8d271c4ba05e9e920381a3
https://doi.org/10.1093/oncolo/oyab040